RemedyRepack Clindamycin Capsules Recall: CGMP Deviations Risk
RemedyRepack Inc. recalls 300 mg Clindamycin HCl capsules due to CGMP deviations. Affected lots expire by Dec 2025. Consumers should contact the company for details.
Recall notice
CGMP Deviations
Contact the company
What happened, in plain English
RemedyRepack Inc. is recalling 300 mg Clindamycin HCl capsules that were repackaged by their company. The recall is due to CGMP deviations, which means the product may not meet quality standards. This could affect safety for people using prescription antibiotics. Read more at govinfonow.com/recall/32173-remedyrepack-clindamycin-capsules-recall-cgmp-deviations-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/32173-remedyrepack-clindamycin-capsules-recall-cgmp-deviations-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0378-2025
Cite this page
“RemedyRepack Clindamycin Capsules Recall: CGMP Deviations Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32173-remedyrepack-clindamycin-capsules-recall-cgmp-deviations-risk. Based on FDA recall #D-0378-2025 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0378-2025%22&limit=1).
Why it’s dangerous
CGMP deviations refer to failures in manufacturing quality control processes. This could mean the capsules do not meet the required safety and purity standards for prescription medication. However, the exact risk level is not specified in the recall notice.
Who’s affected
Prescription users of Clindamycin HCl 300 mg capsules repackaged by RemedyRepack Inc. in Indiana, PA. Those with the specific lot numbers listed in the recall are most at risk.
How to tell if you have this one
Check the product label for the NDC code 70518-3772-00. Look for lot numbers J0826722-121624 (expiring Dec 2025), J0820365-111324 (expiring Nov 2025), or J0814691-101624 (expiring Oct 2025).
- Brand
RemedyRepack- Category
Drug
What to do — step by step
Check Product Details
Look for the NDC code 70518-3772-00 and specific lot numbers listed in the recall.
Where it went and when
Where it was distributed
Distributed in Pennsylvania.
FDA distribution: “PA” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Pennsylvania.
Recall timeline
FDA published this recall 37 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0378-2025 (March 24, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0378-2025 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.